Navigation Links
Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
Date:11/13/2008

BPS Named Contract Manufacturer of Choice, Based on Its Comprehensive Service Portfolio

MOUNTAIN VIEW, Calif., Nov. 13 /PRNewswire/ -- Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan has awarded Baxter's BioPharma Solutions (BPS) with the 2008 North American Frost & Sullivan Customer Service Leadership of the Year Award at the 2008 Excellence in Healthcare Innovation Awards Banquet held in San Antonio, Texas, on Wednesday, November 12, 2008. BPS was recognized for its dedication to providing a wide portfolio of services, strong customer focus, and high customer satisfaction ratings.

"BPS is considered the top choice for outsourcing of manufacturing by respondents from the pharmaceutical and biotechnology industry surveyed in the 2008 Frost & Sullivan Voice of the Customer analysis," says Frost & Sullivan Research Analyst Barath Shankar Subramanian. "BPS is one of the leading contract manufacturing organizations (CMOs) in the sterile manufacturing market -- especially pre-filled syringes and lyophilized vials."

The foundation of BPS' success is its customer-centric service model, Process 360, which offers customers a true partnership experience. It creates transparency and access to the complex process of bringing a molecule to market -- and focuses on scientific expertise, market-differentiating technology, highly-involved customer service, high-quality, reliable supply and bottom-line results.

BPS' robust customer-focused approach ensures constant evaluation of customer needs and satisfaction to make certain the company delivers quality services at all times. It also maintains multiple channels of communication with its clients to facilitate continuous engagement and flow of information with clients.

"In addition to providing contract manufacturing services, BPS also offers upstream and downstream services, such as formulation services, development services and packaging," continues Subramanian. "As a one-stop shop, sponsors are able to take a product from R&D all the way to market, across the global markets, by utilizing these services."

BioPharma Solutions is part of Baxter, a global diversified healthcare company that develops products and therapies to make a meaningful difference in the lives of people with hemophilia, kidney disease, immune disorders and other chronic and acute conditions. With Baxter's legacy of success behind it, BioPharma Solutions provides high-volume contract manufacturing to its customers -- a full range of resources to support initial drug formulation through commercial scale-up, introduction, and life-cycle management. As the leading parenteral contract services leader of prefilled syringes in North America, BioPharma Solutions offers the potential to improve drug safety and efficacy, increase product differentiation and market potential, and enhance patient compliance and end-user preference.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in customer service and satisfaction. Key metrics include mean satisfaction ratings of CMOs across market segments, relative perceived strengths of CMOs, and overall CMO perception. The recipient company has shown tremendous responsiveness to customer needs and has continually focused on achieving customer satisfaction and excellence in customer service.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.awards.frost.com.

Contact:

Jake Wengroff

210.247.3806

jake.wengroff@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award
2. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
3. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
4. Signalife Wins Second Frost & Sullivan Technology Award
5. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
6. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):